Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial
Molina-Vila M, Ponce Aix S, Carcereny E, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Kammler R, Roschitzki-Voser H, Tsourti Z, Karachaliou N, Palmero R, Massutí B, Stahel R, Dafni U, Jordana-Ariza N, Balada-Bel A, Garzón-Ibáñez M, García-Peláez B, Mayo-de-Las-Casas C, Felip E, Curioni Fontecedro A, Gautschi O, Peters S, Rosell R. Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. J Thorac Oncol 2019; 15:416-425.
05.12.2019Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial
05.12.2019J Thorac Oncol 2019; 15:416-425
Molina-Vila Miguel-Angel, Ponce Aix Santiago, Carcereny Enric, Früh Martin, Pless Miklos, Popat Sanjay, Cuffe Sinead, Bidoli Paolo, Kammler Roswitha, Roschitzki-Voser Heidi, Tsourti Zoi, Karachaliou Niki, Palmero Ramon, Massutí Bartomeu, Stahel Rolf A, Dafni Urania, Jordana-Ariza Núria, Balada-Bel Ariadna, Garzón-Ibáñez Mónica, García-Peláez Beatriz, Mayo-de-Las-Casas Clara, Felip Enriqueta, Curioni Fontecedro Alessandra, Gautschi Oliver, Peters Solange, Rosell Rafael
2-fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
Bachner M, Cohn-Cedermark G, Daugaard G, Morelli F, Sella A, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, Oldenburg J, Gillessen Sommer S, Loriot Y, Gross-Goupil M, Zucali P, Horwich A, Germa-Lluch J, Kollmannsberger C, Stoiber F, Fléchon A, Oechsle K, De Santis M. 2-fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 2019; 23:59-64.
04.12.20192-fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
04.12.2019Ann Oncol 2019; 23:59-64
Bachner M, Cohn-Cedermark G, Daugaard G, Morelli F, Sella A, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, Oldenburg J, Gillessen Sommer Silke, Loriot Y, Gross-Goupil M, Zucali P A, Horwich A, Germa-Lluch J-R, Kollmannsberger C, Stoiber F, Fléchon A, Oechsle K, De Santis M
Impact of Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer
Ferraro D, Hermanns T, Kaufmann P, Omlin A, Kranzbühler H, Gablinger R, Müller A, Müller J, Eberli D, Muehlematter U, Garcia Schüler H, Burger I. Impact of Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer. Eur J Nucl Med Mol Imaging 2019
04.12.2019Impact of Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer
04.12.2019Eur J Nucl Med Mol Imaging 2019
Ferraro Daniela A, Hermanns Thomas, Kaufmann Philipp A, Omlin Aurelius, Kranzbühler Helmut, Gablinger Roger, Müller Alexander, Müller Julian, Eberli Daniel, Muehlematter Urs J, Garcia Schüler Helena I, Burger Irene A
Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017"
Curigliano G, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsky P, Gnant M, P Winer E, Burstein H, Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017. Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017". Ann Oncol 2019; 30:1181.
04.12.2019Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017"
04.12.2019Ann Oncol 2019; 30:1181
Curigliano G, Thürlimann Beat, Senn H-J, Piccart-Gebhart M, Regan M M, Colleoni M, Loibl S, Dubsky P, Gnant M, P Winer E, Burstein H J, Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017
Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?
Coates A, Goldhirsch A, Gelber R, Ingle J, Thürlimann B, Senn H. Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?. Ann Oncol 2019; 20:1751-1752.
04.12.2019Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?
04.12.2019Ann Oncol 2019; 20:1751-1752
Coates A S, Goldhirsch A, Gelber R D, Ingle J N, Thürlimann Beat, Senn H-J
Multi-fungal sepsis and mucormycosis of the central nervous system in a patient treated with ibrutinib, a case report and review of the literature
Fehr M, Cathomas G, Graber A, Markert E, Gaus E, Boggian K. Multi-fungal sepsis and mucormycosis of the central nervous system in a patient treated with ibrutinib, a case report and review of the literature. Med Mycol Case Rep 2019; 27:14-16.
03.12.2019Multi-fungal sepsis and mucormycosis of the central nervous system in a patient treated with ibrutinib, a case report and review of the literature
03.12.2019Med Mycol Case Rep 2019; 27:14-16
Fehr Martin, Cathomas Gieri, Graber Anne, Markert Eva, Gaus Elisabeth, Boggian Katia
The tip of the iceberg: predicting PARP inhibitor efficacy in prostate cancer
Gillessen Sommer S, Bristow R. The tip of the iceberg: predicting PARP inhibitor efficacy in prostate cancer. Lancet Oncol 2019; 21:17-19.
02.12.2019The tip of the iceberg: predicting PARP inhibitor efficacy in prostate cancer
02.12.2019Lancet Oncol 2019; 21:17-19
Gillessen Sommer Silke, Bristow Robert G
Impact of treatment decision algorithms on treatment costs in recurrent glioblastoma: a health economic study
Panje C, Putora P, Hundsberger T, Hottinger A, Roelcke U, Pesce G, Herrmann E, Matter-Walstra K. Impact of treatment decision algorithms on treatment costs in recurrent glioblastoma: a health economic study. Swiss Med Wkly 2019; 149:w20153.
02.12.2019Impact of treatment decision algorithms on treatment costs in recurrent glioblastoma: a health economic study
02.12.2019Swiss Med Wkly 2019; 149:w20153
Panje Cédric, Putora Paul Martin, Hundsberger Thomas, Hottinger Andreas F, Roelcke Ulrich, Pesce Gianfranco, Herrmann Evelyn, Matter-Walstra Klazien
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
Tombal B, Padhani A, Olmos D, Oh W, Nilsson S, Mastris K, Logothetis C, Lecouvet F, James N, Hussain M, Parker C, Rubin M, Tannock I, Sweeney C, Suzuki H, Sternberg C, Small E, Shore N, Sella A, Scher H, Schalken J, Heidenreich A, Gleave M, Smith M, Sartor O, Nelson P, Halabi S, Fizazi K, Efstathiou E, de Bono J, Attard G, Omlin A, Soule H, Akaza H, Fanti S, Eeles R, Drake C, De Santis M, Davis I, Daugaard G, Chinnaiyan A, Beltran H, Beer T, Gillessen Sommer S. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2019; 30:e3.
01.12.2019Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
01.12.2019Ann Oncol 2019; 30:e3
Tombal B, Padhani A R, Olmos D, Oh W K, Nilsson S, Mastris K, Logothetis C J, Lecouvet F E, James N D, Hussain M, Parker C, Rubin M A, Tannock I F, Sweeney C J, Suzuki H, Sternberg C N, Small E J, Shore N D, Sella A, Scher H I, Schalken J A, Heidenreich A, Gleave M E, Smith M R, Sartor O, Nelson P S, Halabi S, Fizazi K, Efstathiou E, de Bono J S, Attard G, Omlin Aurelius, Soule H R, Akaza H, Fanti S, Eeles R A, Drake C G, De Santis M, Davis I D, Daugaard G, Chinnaiyan A M, Beltran H, Beer T M, Gillessen Sommer Silke
Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [Radiother. Oncol. 135 (2019) 74-77]
Putora P, Nestle U, Novello S, O' Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Troost E, Van Houtte P, Westeel V, Widder J, Mornex F, McDonald F, Le Pechoux C, Glatzer M, De Ruysscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadiuszko R, Felip E, Früh M, Garrido P, Slotman B. Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [Radiother. Oncol. 135 (2019) 74-77]. Radiother Oncol 2019; 141:332.
01.12.2019Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [Radiother. Oncol. 135 (2019) 74-77]
01.12.2019Radiother Oncol 2019; 141:332
Putora Paul Martin, Nestle Ursula, Novello Silvia, O' Brien Mary, Paz Ares Luis, Peeters Stephanie, Pöttgen Christoph, Ramella Sara, Reck Martin, Troost Esther G C, Van Houtte Paul, Westeel Virginie, Widder Joachim, Mornex Francoise, McDonald Fiona, Le Pechoux Cecile, Glatzer Markus, De Ruysscher Dirk, Faivre-Finn Corinne, Belderbos Jose, Besse Benjamin, Blackhall Fiona, Califano Raffaele, Cappuzzo Federico, de Marinis Filippo, Dziadiuszko Rafal, Felip Enriqueta, Früh Martin, Garrido Pilar, Slotman Ben J
Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project
Herbrand A, Hemkens L, Sricharoenchai S, Novak U, Mc Cord K, Jörger M, Hoogkamer A, Ewald H, Diem S, Briel M, Schmitt A, Kasenda B. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. ESMO Open 2019; 4:e000596.
01.12.2019Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project
01.12.2019ESMO Open 2019; 4:e000596
Herbrand Amanda Katherina, Hemkens Lars G, Sricharoenchai Sirintip, Novak Urban, Mc Cord Kimberly Alba, Jörger Markus, Hoogkamer Anouk, Ewald Hannah, Diem Stefan, Briel Matthias, Schmitt Andreas Michael, Kasenda Benjamin
Feasibility of a large multi-center translational research project for newly diagnosed breast and ovarian cancer patients with affiliated biobank: the BRandO biology and outcome (BiO)-project
De Gregorio A, Rothenbacher D, Janni W, Schmitt M, Kuhn P, Wiesmüller L, Friedl T, De Gregorio N, Ebner F, Felberbaum R, Thiel F, Kühn T, Flock F, Fritz S, Schlicht E, Rempen A, Möller P, Nagel G, Huober J. Feasibility of a large multi-center translational research project for newly diagnosed breast and ovarian cancer patients with affiliated biobank: the BRandO biology and outcome (BiO)-project. Arch Gynecol Obstet 2019; 301:273-281.
28.11.2019Feasibility of a large multi-center translational research project for newly diagnosed breast and ovarian cancer patients with affiliated biobank: the BRandO biology and outcome (BiO)-project
28.11.2019Arch Gynecol Obstet 2019; 301:273-281
De Gregorio Amelie, Rothenbacher Dietrich, Janni Wolfgang, Schmitt Margit, Kuhn Peter, Wiesmüller Lisa, Friedl Thomas Wolfram Paul, De Gregorio Nikolaus, Ebner Florian, Felberbaum Ricardo, Thiel Falk, Kühn Thorsten, Flock Felix, Fritz Steffen, Schlicht Erik, Rempen Andreas, Möller Peter, Nagel Gabriele, Huober Jens
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Antonarakis E, Procopio G, Fukasawa S, Tabata K, Park S, Feyerabend S, Drake C, Wu H, Qiu P, Kim J, Poehlein C, Omlin A, Li C, Piulats J, Gross-Goupil M, Goh J, Ojamaa K, Hoimes C, Vaishampayan U, Berger R, Sezer A, Alanko T, de Wit R, de Bono J. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. J Clin Oncol 2019:JCO1901638.
27.11.2019Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
27.11.2019J Clin Oncol 2019:JCO1901638
Antonarakis Emmanuel S, Procopio Giuseppe, Fukasawa Satoshi, Tabata Ken-Ichi, Park Se Hoon, Feyerabend Susan, Drake Charles G, Wu Haiyan, Qiu Ping, Kim Jeri, Poehlein Christian, Omlin Aurelius, Li Chunde, Piulats Josep M, Gross-Goupil Marine, Goh Jeffrey, Ojamaa Kristiina, Hoimes Christopher J, Vaishampayan Ulka, Berger Ranaan, Sezer Ahmet, Alanko Tuomo, de Wit Ronald, de Bono Johann Sebastian
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
van den Bent M, Zhang H, Balbin O, Vicente S, Cheng Y, Kirsilae T, Zhao S, Tiedt R, Rodón J, Tabatabai G, Jörger M, Lassman A, Wen P, Yung W, Sepulveda J, De Vos F, Azaro A, Wick W. A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. J Neurooncol 2019
27.11.2019A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
27.11.2019J Neurooncol 2019
van den Bent Martin, Zhang Hefei, Balbin O Alejandro, Vicente Sergio, Cheng Yi, Kirsilae Tiina, Zhao Sylvia, Tiedt Ralph, Rodón Jordi, Tabatabai Ghazaleh, Jörger Markus, Lassman Andrew B, Wen Patrick Y, Yung W K Alfred, Sepulveda Juan, De Vos Filip, Azaro Analia, Wick Wolfgang
Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients
Vrabel D, Sevcikova S, Pour L, Stork M, Sandecka V, Jelinek T, Plonkova H, Jarkovsky J, Brožová L, Kubaczkova V, Almasi M, Bezdekova R, Rihova L, Besse L, Sedlarikova L, Hájek R. Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients. Eur J Haematol 2019
25.11.2019Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients
25.11.2019Eur J Haematol 2019
Vrabel David, Sevcikova Sabina, Pour Ludek, Stork Martin, Sandecka Viera, Jelinek Tomas, Plonkova Hana, Jarkovsky Jiri, Brožová Lucie, Kubaczkova Veronika, Almasi Martina, Bezdekova Renata, Rihova Lucie, Besse Lenka, Sedlarikova Lenka, Hájek Roman
Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC
Schett A, Rothschild S, Curioni-Fontecedro A, Krähenbühl S, Früh M, Schmid S, Driessen C, Jörger M. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC. Cancer Chemother Pharmacol 2019; 85:121-131.
19.11.2019Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC
19.11.2019Cancer Chemother Pharmacol 2019; 85:121-131
Schett Anne, Rothschild Sacha I, Curioni-Fontecedro Alessandra, Krähenbühl Stephan, Früh Martin, Schmid S, Driessen Christoph, Jörger Markus
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees
Khoo V, N'Dow J, Necchi A, Neuzillet Y, Oddens J, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel M, Pieters B, Plass K, Remzi M, Müller C, Müller A, Kiltie A, Krege S, Ladoire S, Lara P, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir M, Moschini M, Mostafid H, Retz M, Richenberg J, Turkbey B, Lauridsen S, Valdagni R, Der Heijden A, Van Poppel H, Vartolomei M, Veskimäe E, Vilaseca A, Rivera F, Wiegel T, Wiklund P, Williams A, Zigeuner R, Tombal B, Thalmann G, Rink M, Roghmann F, Rosenberg J, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk R, Smits A, Stenzl A, Horwich A, Kamat A, Witjes J, Arends T, Bamias A, Birtle A, Black P, Bochner B, Bolla M, Boormans J, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Agarwal N, Xylinas E, Babjuk M, Bellmunt J, Bruins H, de Reijke T, De Santis M, Gillessen Sommer S, James N, MacLennan S, Palou J, Powles T, Ribal M, Shariat S, Der Kwast T, Chiti A, Choudhury A, Gontero P, Grubmüller B, Hafeez S, Hansel D, Hartmann A, Hayne D, Henry A, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa B, Geavlete B, Gakis G, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig J, Fanti S, Fonteyne V, Frydenberg M, Futterer J, Jones R. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees. Eur Urol 2019; 77:223-250.
19.11.2019EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees
19.11.2019Eur Urol 2019; 77:223-250
Khoo Vincent, N'Dow James, Necchi Andrea, Neuzillet Yann, Oddens Jorg R, Oldenburg Jan, Osanto Susanne, J G Oyen Wim, Pacheco-Figueiredo Luís, Pappot Helle, Patel Manish I, Pieters Bradley R, Plass Karin, Remzi Mesut, Müller Christoph R, Müller Arndt-Christian, Kiltie Anne E, Krege Susanne, Ladoire Sylvain, Lara Pedro C, Leliveld Annemarie, Linares-Espinós Estefania, Løgager Vibeke, Lorch Anja, Loriot Yohann, Meijer Richard, Mir M Carmen, Moschini Marco, Mostafid Hugh, Retz Margitta, Richenberg Jonathan, Turkbey Baris, Lauridsen Susanne Vahr, Valdagni Riccardo, Der Heijden Antoine G Van, Van Poppel Hein, Vartolomei Mihai D, Veskimäe Erik, Vilaseca Antoni, Rivera Franklin A Vives, Wiegel Thomas, Wiklund Peter, Williams Andrew, Zigeuner Richard, Tombal Bertrand, Thalmann George N, Rink Michael, Roghmann Florian, Rosenberg Jonathan E, Rouprêt Morgan, Rouvière Olivier, Salembier Carl, Salminen Antti, Sargos Paul, Sengupta Shomik, Sherif Amir, Smeenk Robert J, Smits Anita, Stenzl Arnulf, Horwich Alan, Kamat Ashish M, Witjes J Alfred, Arends Tom, Bamias Aristotle, Birtle Alison, Black Peter C, Bochner Bernard H, Bolla Michel, Boormans Joost L, Bossi Alberto, Briganti Alberto, Brummelhuis Iris, Burger Max, Castellano Daniel, Cathomas Richard, Agarwal Neeraj, Xylinas Evanguelos, Babjuk Marek, Bellmunt Joaquim, Bruins H Maxim, de Reijke Theo M, De Santis Maria, Gillessen Sommer Silke, James Nicholas, MacLennan Steven, Palou Juan, Powles Tom, Ribal Maria J, Shariat Shahrokh F, Der Kwast Theo Van, Chiti Arturo, Choudhury Ananya, Gontero Paolo, Grubmüller Bernhard, Hafeez Shaista, Hansel Donna E, Hartmann Arndt, Hayne Dickon, Henry Ann M, Hernandez Virginia, Herr Harry, Herrmann Ken, Hoskin Peter, Huguet Jorge, Jereczek-Fossa Barbara A, Geavlete Bogdan, Gakis Georgios, Compérat Eva, Crabb Simon, Culine Stéphane, De Bari Berardino, De Blok Willem, J L De Visschere Pieter, Decaestecker Karel, Dimitropoulos Konstantinos, Dominguez-Escrig Jose L, Fanti Stefano, Fonteyne Valerie, Frydenberg Mark, Futterer Jurgen J, Jones Rob
Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2 mutated extramammary Paget's disease.
Nordmann T, Messerli-Odermatt O, Meier L, Micaletto S, Coppetti T, Nägeli M, Kamarachev J, Kudura K, Freiberger S, Rordorf T, Mangana J, Braun R, Dummer R. Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2 mutated extramammary Paget's disease. Oncotarget 2019; 10:6647-6650.
19.11.2019Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2 mutated extramammary Paget's disease.
19.11.2019Oncotarget 2019; 10:6647-6650
Nordmann Thierry M, Messerli-Odermatt Olivia, Meier Larissa, Micaletto Sara, Coppetti Thomas, Nägeli Mirjam, Kamarachev Jivko, Kudura Ken, Freiberger Sandra N, Rordorf Tamara, Mangana Joanna, Braun Ralph, Dummer Reinhard
Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial
Witzel I, Untch M, Stickeler E, Schem C, Marme F, Mackelenbergh M, Karn T, Huober J, Lück H, Weber K, Denkert C, Fasching P, Wirtz R, Loibl S, Müller V. Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial. Br J Cancer 2019; 121:1009-1015.
15.11.2019Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial
15.11.2019Br J Cancer 2019; 121:1009-1015
Witzel Isabell, Untch Michael, Stickeler Elmar, Schem Christian, Marme Frederik, Mackelenbergh Marion von, Karn Thomas, Huober Jens, Lück Hans-Joachim, Weber Karsten, Denkert Carsten, Fasching Peter A, Wirtz Ralph, Loibl Sibylle, Müller Volkmar
Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma
Lin Y, Greene C, Boise L, Driessen C, Ferguson I, Marcoulis M, Mariano M, Barwick B, Way G, Wiita A. Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma. Blood Adv 2019; 3:3214-3227.
12.11.2019Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma
12.11.2019Blood Adv 2019; 3:3214-3227
Lin Yu-Hsiu T, Greene Casey S, Boise Lawrence H, Driessen Christoph, Ferguson Ian D, Marcoulis Makeba, Mariano Margarette C, Barwick Benjamin G, Way Gregory P, Wiita Arun P